Join to View Full Profile
3410 Worth StDallas, TX 75246
Phone+1 214-370-1000
Fax+1 214-370-1026
Dr. Nadler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Eric Nadler, MD is a Dallas-based Oncology Specialist with a comprehensive educational background, having completed his education at Harvard Medical School, followed by Residency in Internal Medicine and Fellowship in Hematology and Medical Oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute. His clinical expertise covers various areas including lung, head and neck oncology, sarcomas, and cutaneous malignancies. He has contributed to several publications in esteemed journals like Targeted Oncology and Future Oncology, and actively participated in clinical trials for advancing cancer treatments. Dr. Nadler is also an award winner, having received the Meaningful Use Stage 1 Certification from Centers for Medicare & Medicaid Services in 2012.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2005- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000
Certifications & Licensure
TX State Medical License 2005 - 2027
MA State Medical License 2002 - 2007
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Start of enrollment: 2010 Jun 01
- Optimal Tube Feeding Method in Head and Neck Cancer Patients Start of enrollment: 2015 Feb 01
- Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Publications & Presentations
PubMed
- The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.Misako Nagasaka, Upal Basu Roy, Alexandra Berk, Geoffrey Liu, Eric Nadler
Future Oncology. 2025-04-01 - Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squ...Ferdinandos Skoulidis, Hossein Borghaei, Edward B Garon, Ticiana A Leal, Jacob Kaufman
Therapeutic Advances in Medical Oncology. 2025-01-01 - Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach
Targeted Oncology. 2024-01-01
Press Mentions
US Oncology Research, the US Oncology Network and Ontada Announce Clinical Data Showcased in Plenary and Oral Sessions at ASCO Annual MeetingJune 3rd, 2021
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerApril 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
